Skip to main content
Human Reproduction (Oxford, England) logoLink to Human Reproduction (Oxford, England)
. 2022 Sep 23;37(11):2690–2699. doi: 10.1093/humrep/deac210

Polycystic ovary syndrome and risk of adverse pregnancy outcomes: a registry linkage study from Massachusetts

Leslie V Farland 1,2,, Judy E Stern 3, Chia-Ling Liu 4, Howard J Cabral 5, Charles C Coddington III 6, Hafsatou Diop 7, Dmitry Dukhovny 8, Sunah Hwang 9, Stacey A Missmer 10,11
PMCID: PMC9627555  PMID: 36149255

Abstract

STUDY QUESTION

Do women with polycystic ovary syndrome (PCOS) have a greater risk of adverse pregnancy complications (gestational diabetes, preeclampsia, cesarean section, placental abnormalities) and neonatal outcomes (preterm birth, small for gestational age, prolonged delivery hospitalization) compared to women without a PCOS diagnosis and does this risk vary by BMI, subfertility and fertility treatment utilization?

SUMMARY ANSWER

Deliveries to women with a history of PCOS were at greater risk of complications associated with cardiometabolic function, including gestational diabetes and preeclampsia, as well as preterm birth and prolonged length of delivery hospitalization.

WHAT IS KNOWN ALREADY

Prior research has suggested that women with PCOS may be at increased risk of adverse pregnancy outcomes. However, findings have been inconsistent possibly due to lack of consistent adjustment for confounding factors, small samples size and other sources of bias.

STUDY DESIGN, SIZE, DURATION

Massachusetts deliveries among women ≥18 years old during 2013–2017 from state vital records linked to hospital discharges, observational stays and emergency department visits were linked to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) and the Massachusetts All-Payers Claims Database (APCD).

PARTICIPANTS/MATERIALS, SETTING, METHODS

PCOS was identified by ICD9 and ICD10 codes in APCD prior to index delivery. Relative risks (RRs) and 95% CI for pregnancy and delivery complications were modeled using generalized estimating equations with a log link and a Poisson distribution to take multiple cycles into account and were adjusted a priori for maternal age, BMI, race/ethnicity, education, plurality, birth year, chronic hypertension and chronic diabetes. Tests for homogeneity investigated differences between maternal pre-pregnancy BMI categories (<30, ≥30, <25 and ≥25 kg/m2) and between non-infertile deliveries and deliveries that used ART or had a history of subfertility (defined by birth certificates, SART CORS records, APCD or hospital records).

MAIN RESULTS AND THE ROLE OF CHANCE

Among 91 825 deliveries, 3.9% had a history of PCOS. Women with a history of PCOS had a 51% greater risk of gestational diabetes (CI: 1.38–1.65) and a 25% greater risk of preeclampsia (CI: 1.15–1.35) compared to women without a diagnosis of PCOS. Neonates born to women with a history of PCOS were more likely to be born preterm (RR: 1.17, CI: 1.06–1.29) and more likely to have a prolonged delivery hospitalization after additionally adjusting for gestational age (RR: 1.23, CI: 1.09–1.40) compared to those of women without a diagnosis of PCOS. The risk for gestational diabetes for women with PCOS was greater among women with a pre-pregnancy BMI <30 kg/m2.

LIMITATIONS, REASONS FOR CAUTION

PCOS was defined by ICD documentation prior to delivery so there may be women with undiagnosed PCOS or PCOS diagnosed after delivery included in the unexposed group. The study population is limited to deliveries within Massachusetts among most private insurance payers and inpatient or observational hospitalization in Massachusetts during the follow-up window, therefore there may be diagnoses and or deliveries outside of the state or outside of our sample that were not captured.

WIDER IMPLICATIONS OF THE FINDINGS

In this population-based study, women with a history of PCOS were at greater risk of pregnancy complications associated with cardiometabolic function and preterm birth. Obstetricians should be aware of patients’ PCOS status and closely monitor for potential pregnancy complications to improve maternal and infant perinatal health outcomes.

STUDY FUNDING/COMPETING INTEREST(S)

This work was supported by the NIH (R01HD067270). S.A.M. receives grant funding from NIH, AbbVie and the Marriot Family Foundation; payment/honoraria from the University of British Columbia, World Endometriosis Research Foundation and Huilun Shanghai; travel support for attending meetings for ESHRE 2019, IASP 2019, National Endometriosis Network UK meeting 2019; SRI 2022, ESHRE 2022; participates on the data safety monitoring board/advisory board for AbbVie, Roche, Frontiers in Reproductive Health; and has a leadership role in the Society for Women’s Health Research, World Endometriosis Research Foundation, World Endometriosis Society, American Society for Reproductive Medicine and ESHRE. The other authors have no conflicts of interest.

TRIAL REGISTRATION NUMBER

N/A.

Keywords: polycystic ovary syndrome, gestational age, gestational diabetes, preterm birth, adverse pregnancy outcomes, PCOS, low birth weight, preeclampsia, pregnancy-induced hypertension

Introduction

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, ovarian dysfunction and polycystic ovarian morphology (Legro et al., 2013; Teede et al., 2018) and is the most common endocrine disorder in women, burdening approximately 6–15% of reproductive-aged women (Fauser et al., 2012; Bozdag et al., 2016). Phenotypic traits associated with PCOS, such as obesity, metabolic syndrome, impaired glucose tolerance, insulin resistance and infertility (Franks, 1995), are also associated with higher prevalence of adverse pregnancy outcomes. Therefore, there has been a great deal of interest in the influence of PCOS on adverse outcomes during pregnancy.

Prior meta-analyses and systematic reviews have suggested that deliveries to women with a history of PCOS are at an increased risk of pregnancy complications (Kjerulff et al., 2011; Qin et al., 2013; Palomba et al., 2015; Yu et al., 2016; Gilbert et al., 2018; Bahri Khomami et al., 2019; Sha et al., 2019), including an elevated risk of gestational diabetes, pregnancy-induced hypertension (PIH) and preterm birth. However, findings from some studies have been inconsistent and not all analyses have adjusted for potential confounding factors, such as BMI or chronic diabetes (Palomba et al., 2015). Moreover, many studies on PCOS and adverse pregnancy outcomes are conducted among a small number of women, limiting statistical power and generalizability. Among the most recent meta-analyses, 70% of the studies included had fewer than 100 deliveries to women with a history of PCOS (Yu et al., 2016) and half of the studies were considered to have moderate to high risk of bias (Bahri Khomami et al., 2019).

To improve upon these previous limitations, we conducted an analysis among Massachusetts deliveries from 2013 to 2017. Specifically, we investigated whether women with a previous history of PCOS had greater risk of adverse maternal and pregnancy outcomes compared to women without a diagnosis of PCOS accounting for potential confounding factors. We also investigated effect modification by maternal pre-pregnancy BMI and by history of subfertility/infertility or ART usage.

Materials and methods

This analysis linked data from three sources: (i) Massachusetts Pregnancy to Early Life Longitudinal (PELL) data system, (ii) Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) and (iii) Massachusetts All-Payers Claims Database (APCD). The study had IRB approvals from the Massachusetts Department of Public Health and Dartmouth-Hitchcock Health.

As described in detail previously (Kotelchuck et al., 2014), the Massachusetts Outcome Study of Assisted Reproductive Technology (MOSART) database was created by linking SART CORS deliveries from 1 July 2004 to 31 December 2017 to birth certificates and fetal death records using mother’s first and last name, father’s last name, mother’s date of birth and date of delivery. Between 2004 and 2017, the linkage rates were 91.5% overall and 94.9% for those in which both ART cycle patient zip code and treatment clinic were located in Massachusetts.

APCD is comprised of insurance claims from most public and private insurance payers in Massachusetts. The APCD and MOSART data from 1 January 2013 to 31 December 2017 were linked, as described in detail previously (Stern et al., 2021a,b). Mothers with MassHealth (Medicaid Program in Massachusetts) at any time during the study period were excluded. This linkage was executed through a Memorandum of Understanding among the Center for Health Information and Analysis (CHIA) that maintains and houses APCD, the Massachusetts Department of Public Health (MDPH) and project principal investigators. Maternal (date of birth, first name, last name and zip code) and infant (date of birth, first name, last name, sex and zip code) information from the MOSART database was submitted to CHIA for linkage using the member eligibility file. CHIA matched and then extracted the APCD non-MassHealth medical claim records for the linked mothers and children and sent these de-identified data back to MDPH.

History of PCOS was categorized based on ICD9 and ICD10 codes reported to APCD (ICD9:256.4, ICD10: E28.2). Participants were categorized as having a history of PCOS if there was a date of service for the condition in APCD that was on or before their index delivery date.

Maternal, neonatal and infant outcomes

Maternal outcomes of interest included: gestational diabetes, gestational hypertension/preeclampsia/eclampsia, cesarean delivery and placental abnormalities. Data on gestational diabetes, hypertension during pregnancy including preeclampsia and eclampsia as well as placental abnormalities were identified in PELL from either the birth certificate, hospital discharge delivery record or pre-delivery (within 280 days before delivery) ICD9 and ICD10 codes (642.3–642.6, 642.9, O11, O13–O16 for pregnancy-related hypertension/preeclampsia/eclampsia; 648.8, O24.4, O24.9 for gestational diabetes; and 641.0–641.2, 663.5, 667.0, 762.1, O45, P02.1, O43.21, O44, O69.4 for placental abnormalities). Information on cesarean delivery was obtained from the birth certificate. Outcome diagnoses made in the outpatient setting were not available.

Neonatal outcomes investigated were large for gestational age, small for gestational age, low birthweight, prematurity and prolonged delivery hospital stay. Large and small for gestational age were defined as a birthweight Z-score above or below the 10th percentile, respectively and based on the SD score of the value for each individual from the mean value of the Massachusetts reference population divided by the SD for that reference population (Oken et al., 2003). To calculate population-specific birthweight Z scores, we generated gender-, race/ethnicity- and gestation length-specific birthweight means and SDs using Massachusetts data for all live births from 1998 to 2017. Low birthweight was defined as <2500 g using information on birthweight from the birth certificate. The birth certificate provided information on length of gestation and was based on clinical estimates of first-trimester ultrasound or last menstrual period. Premature birth was defined as a gestational length of <37 weeks. Prolonged delivery hospital stay was defined as a hospital stay of >3 days for vaginal delivery or >5 days for cesarean delivery and was limited to deliveries in which gestational age was ≥35 weeks, and with known data on mode of delivery. Mode of delivery and gestational age were obtained from birth certificates and length of birth hospitalization was obtained from neonatal hospital discharge records.

We also investigated risk of infant conditions, including abnormalities of infectious disease, cardiovascular, respiratory, gastrointestinal/nutritional, neurologic and hematologic systems during the first year of life. These conditions were grouped by system based on ICD9 and ICD10 codes, as has been described in detail previously (Hwang et al., 2018) and were restricted to live born infants in 2013–2016 to allow capture of conditions up to 1 year after birth. These diagnoses were identified from inpatient hospital stays (including hospital discharges, observational stays and Emergency Room visits) and did not include outpatient visits.

Subfertility, infertility and ART treatment

We classified deliveries into groups of non-infertile, subfertile/infertile or ART as these groupings have been informative on previous analyses conducted by our research group. Index deliveries were classified as having utilized ART if the delivery was linked to an ART cycle in the SART CORS database. Cycles in the SART CORS database include IVF and related techniques that involve manipulation of eggs and embryos. They do not include ovulation induction, intrauterine insemination or other less invasive techniques. Deliveries were classified as ‘subfertile’ if they met one of the following criteria: (i) indicated infertility treatment on the birth or fetal death certificate but no linkage to SART CORS in the index delivery, (ii) utilized an ICD code for infertility (ICD codes 628 and V230; ICD 10 O09.00–O09.03 and N97.0–N97.9) during a prior hospitalization or (iii) had a prior delivery with either an indication of infertility treatment or linkage to SART CORS. Deliveries were considered ‘infertile’ if the delivery had a prior APCD outpatient or inpatient claim with provider-confirmed diagnosis of infertility. Subfertile and infertile deliveries were combined for this analysis. The subfertile/infertile category excluded those with ART treatment to conceive the index pregnancy. Deliveries were classified as ‘non-infertile’ if they did not fall into any of the other categories (Declercq et al., 2014).

Statistical analyses

The relative risks (RRs) and 95% CIs of adverse outcomes were estimated using generalized estimating equations with a log-link and a Poisson distribution to account for multiple deliveries by the same women. Multivariable models were a priori adjusted for maternal age (continuous), maternal BMI prior to pregnancy (<25, ≥25 kg/m2, unknown), maternal race/ethnicity (non-Hispanic White, other race/ethnicity, unknown), maternal education (high school and/or some college, completed college, unknown), plurality of delivery (singleton, multiple), birth year (2013–2017 ordinal categorical calendar years), history of chronic maternal hypertension, history of chronic maternal diabetes and gestational age (continuous), where appropriate. Information on maternal covariates, including pre-pregnancy BMI, was obtained from the birth certificate. Information on chronic hypertension and diabetes prior to pregnancy was obtained from both the birth certificate and the hospital discharge records. In sensitivity analyses for the outcome, gestational diabetes, we excluded women with a history of pre-existing diabetes.

We investigated effect modification by BMI using two categorizations to be consistent with prior analyses (BMI < 30 versus BMI ≥30 kg/m2; and BMI < 25 versus BMI ≥ 25 kg/m2) and infertility history overall (non-infertile, subfertile/infertile, ART delivery) and comparing non-infertile to other groups by stratifying deliveries into categories. We performed tests for homogeneity by using generalized estimating equations score tests with type 3 estimates. We also restricted our analyses to primiparous deliveries. In accordance with guidelines from CHIA, we suppressed any counts that were <11. Analyses were performed in SAS/STAT software 14.3 (SAS Institute, Cary NC, USA). A statistical significance threshold of <0.05 was used.

Results

Our sample included 3552 deliveries to women with a history of PCOS and 88 273 deliveries to women without a diagnosis of PCOS (Table I). We observed no meaningful difference in age at delivery between women with and without a diagnosis of PCOS. Women with a history of PCOS were more likely to be overweight or obese prior to pregnancy (51.0% versus 35.5%) and to have used ART (20.8% versus 7.9%) or to experience subfertility or infertility (47.7% versus 13.3%). Women with a history of PCOS were less likely to have a history of two or more previous births (43.7% versus 51.4%).

Table I.

Characteristics of study sample deliveries to women aged ≥18 between 1 October 2013 and 31 December 2017.

No diagnosis of PCOS
Diagnosis of PCOS
n % n %
Total 88 273 100.0 3552 100.0
Maternal age (years)
 Range 18–56 18–50
 Mean (SD) 33.11 (4.12) 33.23 (3.80)
 18–29 15 613 17.7 522 14.7
 30–34 41 511 47.0 1778 50.1
 35–37 18 782 21.3 764 21.5
 38–40 8917 10.1 379 10.7
 >40 3450 3.9 109 3.1
Race/Ethnicity
 Hispanic 4085 4.6 173 4.9
 Non-Hispanic White 66 535 75.4 2678 75.4
 Non-Hispanic Black 2967 3.4 118 3.3
 Non-Hispanic Asian 12 594 14.3 492 13.9
 Other non-Hispanic 386 0.4 10 0.3
 Unknown 1706 1.9 81 2.3
BMI (kg/m2)
 <22.5 33 916 38.4 986 27.8
 22.5 to <25.0 20 274 23.0 648 18.2
 25.0 to <30.0 19 580 22.2 834 23.5
 30.0+ 11 746 13.3 978 27.5
 Unknown 2757 3.1 106 3.0
Highest level of education
 <HS/HS graduate 2871 3.3 106 3.0
 Some college 10 760 12.2 443 12.5
 College graduate 72 637 82.3 2897 81.6
 Unknown 2005 2.3 106 3.0
Health insurance at delivery
 Private 78 541 89.0 3159 88.9
 Public/Free Care 4318 4.9 138 3.9
 Self-pay 5363 6.1 249 7.0
 Unknown 51 0.1 6 0.2
Gravidity a
 1 34 131 38.7 1508 42.5
 2 29 409 33.3 1138 32.0
 3–18 24 378 27.6 891 25.1
 Unknown 355 0.4 15 0.4
Parity
 1 42 811 48.5 1997 56.2
 2 32 737 37.1 1215 34.2
 3–15 12 624 14.3 338 9.5
 Unknown 101 0.1 2 0.1
Plurality
 Singletons 86 199 97.7 3404 95.8
 Multiples 2074 2.3 148 4.2
Fertility group
 ART 6949 7.9 740 20.8
 Subfertile/infertile 11 736 13.3 1696 47.7
 Non-infertile 69 588 78.8 1116 31.4
Year of birth
 2013 5547 6.3 84 2.4
 2014 21 983 24.9 526 14.8
 2015 21 379 24.2 799 22.5
 2016 20 382 23.1 1059 29.8
 2017 18 982 21.5 1084 30.5

PCOS, polycystic ovary syndrome; HS, high school.

a

No gravidity data from fetal deaths.

In multivariable models adjusted for maternal age, pre-pregnancy BMI, maternal education, maternal race/ethnicity, plurality, birth year and history of hypertension and diabetes, women with a history of PCOS had a 51% greater risk of gestational diabetes (RR: 1.51, 95% CI: 1.38–1.65) compared to women without a diagnosis of PCOS (Table II). In sensitivity analyses excluding women with pre-existing diabetes, this association remained consistent (RR: 1.56, 95% CI: 1.43–1.71). We also observed that women with a history of PCOS were at greater risk of PIH, preeclampsia and eclampsia (RR: 1.25, 95% CI: 1.15–1.35), as well as higher risk of cesarean section (RR: 1.07, 95% CI: 1.02–1.11) compared to women never diagnosed with PCOS. We did not observe an association between PCOS and placental abnormalities.

Table II.

Association between history of polycystic ovary syndrome (PCOS) prior to delivery and adverse pregnancy outcomes among deliveries to women in study sample aged ≥18 between 1 October 2013 and 31 December 2017.

No diagnosis of PCOS
Diagnosis of PCOS
Relative risk (95% CI)1
n % n % Crude Adjusted2
Total deliveries 88 273 100.0 3552 100.0
Maternal outcomes
 Gestational diabetes 6690 7.6 490 13.8 1.85 (1.70–2.02) 1.51 (1.38–1.65)
 PIH/eclampsia/preeclampsia 9077 10.3 576 16.2 1.57 (1.45–1.70) 1.25 (1.15–1.35)
 Caesarean section3 28 084 31.8 1273 35.8 1.14 (1.10–1.20) 1.07 (1.02–1.11)
 Placental abnormalities 2521 2.9 102 2.9 1.01 (0.83–1.22) 1.06 (0.87–1.28)
Infant outcomes
 Total infants 90 373 100.0 3704 100.0
 Total live births 90 129 99.7 3690 100.0
 Large for gestational age4 8251 9.4 350 9.7 1.05 (0.95–1.17) 0.97 (0.87–1.07)
 Small for gestational age4 6337 7.2 291 8.1 1.10 (0.98–1.24) 1.11 (0.99–1.25)
 Low birthweight (<2500 g)5 5800 6.4 378 10.2 1.49 (1.27–1.74) 1.07 (0.96–1.19)
 Low birthweight (<2500 g)5 full-term only 1670 2.0 100 3.1 1.53 (1.24–1.88) 1.20 (0.97–1.47)
 Preterm birth (<37 weeks) 6880 7.7 435 11.9 1.14 (0.65–2.01) 1.17 (1.06–1.29)
 Neonatal prolonged hospital stay4,6,7 3762 4.3 232 6.7 1.52 (1.32–1.74) 1.23 (1.09–1.40)
Neonatal conditions
 Infectious disease conditions7,8 815 1.2 56 2.2 1.89 (1.44–2.49) 1.40 (1.05–1.88)
 Cardiovascular conditions7,8 1534 2.2 81 3.1 1.43 (1.14–1.80) 1.17 (0.93–1.46)
 Respiratory conditions7,8 11 688 16.5 536 20.8 1.26 (1.17–1.37) 1.09 (1.01–1.19)
 Gastrointestinal/nutritional conditions7,8 4448 6.3 247 9.6 1.53 (1.34–1.76) 1.13 (0.96–1.32)
 Neurologic conditions7,8 2836 4.0 127 4.9 1.23 (1.03–1.46) 1.14 (0.95–1.36)
 Hematologic conditions7,8 9751 13.8 486 18.9 1.39 (1.28–1.52) 1.01 (0.93–1.10)
1

Crude and adjusted relative risk approximated using general estimating equations with a log link and Poisson distribution to take into account multiple deliveries by the same women.

2

Multivariate models adjusted for maternal age (continuous), BMI (<25.0, 25.0+, unknown), race (non-Hispanic White, other race/ethnicity, unknown), education (high school + some college, completed college, unknown), plurality (singleton, multiples), birth year (2013–2017 ordinal categorical variable) and history of hypertension or diabetes.

3

Excluding those with unknown mode of delivery.

4

Limited to live births only.

5

Multivariable model additionally adjusted for fertility treatment.

6

Limited analysis to those whose gestational age ≥35 weeks, with known data on mode of delivery and birth hospital records. Prolonged stay defined as >3 days for vaginal delivery or >5 days for C-section.

7

Relative risk additionally adjusted for gestational age (continuous variable, range 17–44), excluding those with unknown GA.

8

Limited to live births 1 October 2013–31 December 2016 (to allow 1-year follow-up).

PIH, pregnancy-induced hypertension.

Women with a history of PCOS were more likely to deliver prematurely (<37 weeks gestation) (RR: 1.17, 95% CI: 1.06–1.29) compared to women without a diagnosis of PCOS (Table II). Infants born to mothers with a history of PCOS were more likely to be low birthweight in crude models (RR: 1.49, 95% CI: 1.27–1.74). However, this association attenuated and was no longer statistically significant in adjusted models (RR: 1.07, 95% CI: 0.96–1.19), which was primarily driven by adjustment for history of hypertension and diabetes and adjustment for fertility groups. While the association between PCOS and low birthweight did not vary overall by fertility groups (Table III) (P-value 0.12), we did observe differences between fertile and ART groups when assessed separately (P-value, test for homogeneity: 0.03). Among ART pregnancies, PCOS was not associated with low birthweight (RR: 1.05, 95% CI: 0.88–1.24), while among fertile deliveries PCOS was associated with low birthweight (RR: 1.28, 95% CI: 1.01–1.61). We observed a more modest, association between history of PCOS and risk of having an infant that is small for gestational age (RR: 1.11, 95% CI: 0.99–1.25) that did not meet the threshold of statistical significance. We also observed that infants born to mothers with a history of PCOS were more likely to have a prolonged neonatal hospital stay (RR: 1.23, 95% CI: 1.09–1.40) and to be diagnosed with infectious disease conditions (RR: 1.40, 95% CI: 1.05–1.88) or respiratory conditions (RR: 1.09, 95% CI: 1.01–1.19) in multivariable models additionally adjusted for gestational age. When analyses were restricted to primiparous deliveries, the majority of findings remained consistent (Supplementary Table SI). The association with PCOS and risk of cesarean section attenuated and was no longer statistically significant (RR: 1.01, 95% CI: 0.95–1.07).

Table III.

Association between history of polycystic ovary syndrome (PCOS) and adverse pregnancy outcomes among deliveries by study sample women aged ≥18 between 1 October 2013 and 31 December 2017, stratified by history of subfertility/infertility treatment.

No diagnosis of PCOS
Diagnosis of PCOS
Adjusted relative risk (95% CI)1 P-value test for homogeneity2
n % n %
Gestational diabetes
 Non-infertile 5001 7.2 135 12.1 1.37 (1.17–1.61) 0.51
 Subfertility/infertility 1005 8.6 235 13.9 1.54 (1.34–1.76)
 ART 684 9.8 120 16.2 1.42 (1.17–1.72)
PIH/eclampsia/preeclampsia
 Non-infertile 6707 9.6 168 15.1 1.27 (1.10–1.47) 0.24
 Subfertility/infertility 1272 10.8 236 13.9 1.13 (0.99–1.28)
 ART 1098 15.8 172 23.2 1.25 (1.08–1.46)
Cesarean section3
 Non-infertile 20 395 29.3 363 32.5 1.07 (0.99–1.16) 0.16
 Subfertility/infertility 4307 36.7 575 33.9 0.96 (0.90–1.03)
 ART 3382 48.7 335 45.3 0.98 (0.90–1.06)
Small for gestational age4
 Non-infertile 4715 6.8 81 7.4 1.11 (0.89–1.39) 0.52
 Subfertility/infertility 894 7.6 141 8.3 1.11 (0.93–1.32)
 ART 728 9.5 69 8.7 1.00 (0.78–1.28)
Large for gestational age4
 Non-infertile 6470 9.3 107 9.8 0.93 (0.78–1.12) 0.66
 Subfertility/infertility 1149 9.8 176 10.3 1.01 (0.86–1.17)
 ART 632 8.3 67 8.4 0.90 (0.70–1.15)
Low birthweight (<2500 g)
 Non-infertile 3489 5.0 72 6.4 1.28 (1.01–1.61) 0.12
 Subfertility/infertility 958 7.9 167 9.5 1.14 (0.97–1.33)
 ART 1353 17.2 139 16.9 1.05 (0.88–1.24)
Preterm birth (<37 weeks)
 Non-infertile 4179 6.0 83 7.4 1.21 (0.97–1.52) 0.29
 Subfertility/infertility 1135 9.5 184 10.6 1.04 (0.89–1.21)
 ART 1566 20.1 168 20.6 1.11 (0.94–1.30)
Neonatal prolonged hospital stay4,5
 Non-infertile 2582 3.8 59 5.5 1.25 (0.99–1.59) 0.52
 Subfertility/infertility 535 4.7 98 5.9 1.20 (0.98–1.46)
 ART 645 9.1 75 10.2 1.11 (0.88–1.41)
1

Crude and adjusted relative risk approximated using general estimating equations with a log link and Poisson distribution to take into account multiple deliveries by the same women; multivariate models adjusted for maternal age (continuous), BMI (<25.0, 25.0+, unknown), race (non-Hispanic White, other race/ethnicity, unknown), education (high school + some college, completed college, unknown), plurality (singleton, multiples), birth year (2013–2017 ordinal categorical variable) and history of hypertension or diabetes.

2

Based on generalized estimating equations type 3 estimates.

3

Excluding those with unknown mode of delivery.

4

Limited to live births only.

5

Limited analysis to those whose gestational age ≥35 weeks, with known data on mode of delivery and birth hospital records.

PIH, pregnancy-induced hypertension.

We observed that the association between PCOS and maternal morbidity varied by BMI (<30 versus ≥30 kg/m2) for gestational diabetes (P-value, test for homogeneity: <0.01) (Table IV). Specifically, among women with a BMI <30 kg/m2, PCOS was associated with a greater risk of gestational diabetes (RR: 1.60, 95% CI: 1.42–1.80), than among women with a BMI ≥30 kg/m2 (gestational diabetes RR: 1.37, 95% CI: 1.21–1.57). When stratifying by BMI <25 versus ≥25 kg/m2, we observed that the risk of PIH/eclampsia/preeclampsia varied by BMI (Supplementary Table SII). Among women with a BMI ≥25 kg/m2, PCOS diagnosis was associated with a 35% greater risk of PIH/eclampsia/preeclampsia (95% CI: 1.23–1.48), while among women with a BMI <25, we observed no association between PCOS and PIH/eclampsia/preeclampsia (RR: 1.04, 95% CI: 0.88–1.24).

Table IV.

Association between history of polycystic ovary syndrome (PCOS) and adverse pregnancy outcomes among deliveries in study sample women aged ≥18 between 1 October 2013 and 31 December 2017, stratified by BMI.*

No diagnosis of PCOS
Diagnosis of PCOS
Adjusted relative risk (95% CI)1 P-value test for homogeneity2
n % n %
Gestational diabetes
 BMI < 30 4657 6.3 259 10.5 1.60 (1.42–1.80) <0.01
 BMI ≥ 30 1802 15.3 213 21.8 1.37 (1.21–1.57)
PIH/eclampsia/preeclampsia
 BMI < 30 6317 8.6 274 11.1 1.16 (1.03–1.31) 0.74
 BMI ≥ 30 2458 20.9 282 28.8 1.30 (1.17–1.44)
Cesarean section3
 BMI < 30 21 908 29.7 762 30.9 1.05 (0.99–1.11) 0.96
 BMI ≥ 30 5289 45.0 465 47.5 1.04 (0.99–1.11)
Small for gestational age4
 BMI < 30 5474 7.4 233 9.3 1.14 (1.00–1.30) 0.28
 BMI ≥ 30 725 6.1 62 6.3 0.96 (0.74–1.24)
Large for gestational age4
 BMI < 30 6237 8.4 193 7.7 0.93 (0.81–1.07) 0.75
 BMI ≥ 30 1729 14.7 134 13.6 0.94 (0.79–1.11)
Low birthweight (<2500 g)
 BMI < 30 4708 6.2 262 10.2 1.22 (1.08–1.38) 0.32
 BMI ≥ 30 833 6.9 105 10.3 1.15 (0.93–1.43)
Preterm birth (<37 weeks)
 BMI < 30 5570 7.4 299 11.7 1.22 (1.08–1.37) 0.15
 BMI ≥ 30 1077 9.0 123 12.2 1.11 (0.91–1.35)
Neonatal prolonged hospital stay4,5
 BMI < 30 3078 4.2 152 6.2 1.13 (0.97–1.31) 0.63
 BMI ≥ 30 570 5.0 72 7.6 1.30 (1.04–1.64)
*

Analyses are limited to those with known BMI.

1

Crude and adjusted relative risk approximated using general estimating equations with a log link and Poisson distribution to take into account multiple deliveries by the same women; multivariate models adjusted for maternal age (continuous), race (non-Hispanic White, other race/ethnicity, unknown), education (high school + some college, completed college, unknown), plurality (singleton, multiples), birth year (2013–2017 ordinal categorical variable) and history of hypertension or diabetes.

2

Based on generalized estimating equations type 3 estimates.

3

Excluding those with unknown mode of delivery.

4

Limited to live births only.

5

Limited analysis to those whose gestational age ≥35 weeks, with known data on mode of delivery and birth hospital records.

PIH, pregnancy-induced hypertension.

The association between history of PCOS and risk of maternal and neonatal outcomes did not vary within each fertility group (Table III).

Discussion

Overall, we observed that women with a history of PCOS were more likely to experience gestational diabetes, PIH/eclampsia/preeclampsia and cesarean delivery. Neonates born to women with history of PCOS were more likely to be born premature, and require a prolonged neonatal hospital stay. Infants born to women with a history of PCOS were more likely to experience infectious disease conditions or respiratory conditions. The association between PCOS and gestational diabetes was strongest among women with a pre-pregnancy BMI <30 kg/m2. We did not observe any statistically significant effect modification in the association between PCOS and adverse pregnancy outcomes by fertility groups.

Insulin resistance and hyperinsulinemia are intrinsic in the pathophysiology of PCOS (Palomba et al., 2015) and occur independently of obesity (Stepto et al., 2013). Our findings are in agreement with previous research which found that women with PCOS are at a 2- to 4-fold increased risk of gestational diabetes during pregnancy (Kjerulff et al., 2011; Qin et al., 2013; Bahri Khomami et al., 2019; by Mills et al., 2020b). Our observed effect estimate is more modest (RR: 1.51) and closer to the effect size in a recently published population-based cohort study by Mills et al. (2020b) (RR: 2.19). Both analyses were able to adjust for important confounding factors (Correia et al., 2020), such as pre-pregnancy BMI, hypertension and diabetes, which may contribute to lower adjusted effect estimates. In analyses stratified by BMI, we observed that the association between PCOS and gestational diabetes was stronger among women with a pre-pregnancy BMI <30 kg/m2 (RR: 1.60). However, among women with a pre-pregnancy BMI ≥30 kg/m2 we still observed a statistically significant, yet more modest association (RR: 1.37). Similarly, prior meta-analyses have observed stronger associations among women with a BMI <30 kg/m2 (meta-analysis odds ratio (OR): 3.25) compared to women with a BMI ≥30 kg/m2 (meta-analysis OR: 1.43) (Bahri Khomami et al., 2019), suggesting that the influence of PCOS diagnosis on gestational diabetes risk is less among women with BMI ≥30 kg/m2 who may have other competing factors influencing risk. The individual and combined influence of BMI synergistic with insulin resistance on pregnancy outcomes is an important topic for continued research.

We observed that women with PCOS had a modest increased risk of hypertensive disorders of pregnancy (RR: 1.25), consistent with prior meta-analyses (Kjerulff et al., 2011; Qin et al., 2013; Yu et al., 2016; Bahri Khomami et al., 2019) and recent studies (Mills et al., 2020b). We observed that the association with hypertensive disorders varied by pre-pregnancy BMI when 25 kg/m2 was used as the categorization (P-value, test for homogeneity: <0.05; Supplementary Table SII), but not when 30 kg/m2 was used (P-value, test for homogeneity: 0.74; Table IV). Women with a pre-pregnancy BMI ≥25 kg/m2 had a greater risk (RR: 1.35) than women with a lower pre-pregnancy BMI (RR: 1.04). PCOS is associated with metabolic syndrome (Palomba et al., 2015; Bahri Khomami et al., 2019), which may increase the risk of hypertensive disorders during pregnancy.

We observed no association between history of PCOS and placental abnormalities, which is in contrast with one published study which observed an increased risk of placental abruption among women with PCOS (OR: 1.63) (Mills et al., 2020a). Women with PCOS have been hypothesized to have problems with placentation that may lead to negative downstream pregnancy outcomes (Palomba et al., 2015). Future research is needed to understand whether PCOS has any influence on placental abnormalities as well as normal placental function.

Among neonatal outcomes, we observed that women with a history of PCOS had a 20% increased risk of low birthweight among full-term deliveries and an 11% increased risk of small for gestational age. We also observed that women with a history of PCOS had an increased risk of preterm delivery (RR: 1.17). Elevated risk of small for gestational age has been observed in some (Kjerulff et al., 2011; Yu et al., 2016; Foroozanfard et al., 2020) but not all analyses (Boomsma et al., 2006; Mills et al., 2020a). These differences may be influenced by plurality and adjustment for potential confounding factors. Preterm delivery has been shown to be associated with PCOS history in most recent studies and meta-analyses (Boomsma et al., 2006; Kjerulff et al., 2011; Qin et al., 2013; Naver et al., 2014; Mills et al., 2020a; Valgeirsdottir et al., 2021). Again, our findings are of a smaller magnitude of effect (RR: 1.17) compared to previous reports from meta-analyses (ORs range: 2.20–1.75) (Boomsma et al., 2006; Kjerulff et al., 2011; Qin et al., 2013) but similar in magnitude to a recently published large, retrospective analysis using administrative claims data (RR: 1.37) (Mills et al., 2020a). Future work should focus on disentangling whether the consistently observed association between PCOS and preterm birth is driven by spontaneous or medically indicated preterm birth.

We observed that infants born to women with a history of PCOS had a 29% greater risk for prolonged neonatal delivery hospital stay, defined as >3 days for vaginal deliveries and >5 days for cesarean section, compared to infants born to women without a history of PCOS. Prior research has suggested that neonates born to women with a history of PCOS are more likely to be admitted to the neonatal intensive care unit and have a lower Apgar score following delivery (Palomba et al., 2015).

When we investigated infant health conditions associated with PCOS we observed that liveborn infants born to mothers with a history of PCOS were more likely to be diagnosed with respiratory conditions or infectious conditions within the first year of life. A recent meta-analysis reported that babies born to people with PCOS were 24% more likely to have respiratory distress than those born to people without PCOS, but this finding did not reach statistical significance (95% CI: 0.80–1.93) and only included four studies. There is also research suggesting that children born to women with PCOS may have a higher risk for asthma later in life (Doherty et al., 2015). Recent research has suggested that women with PCOS are more likely to develop maternal infections (Koster et al., 2015; Mills et al., 2020a); however, there has been limited research on childhood infectious disease outcomes. Future research should focus on understanding early life outcomes for children born to mothers with PCOS.

While this study has many strengths including its large sample size and ability to control for several potential confounding factors, there are also important limitations that must be considered. PCOS can be challenging to diagnose, with varying criteria necessary for diagnosis, leaving the possibility of misdiagnosis of those defined as having PCOS. It is also likely that there are undiagnosed women erroneously included in our unexposed group who do have a history of PCOS. This underdiagnosis may be increased by our reliance on ICD codes for PCOS diagnosis, and therefore our data may miss any clinical documentation of PCOS that did not include an ICD billing code before delivery. This underdiagnosis may explain the relatively low prevalence of history of PCOS (4%) observed in this general population sample. Additionally, our data set is inherently restricted to women with PCOS who gave birth following their PCOS diagnosis. Therefore, we may expect the prevalence of PCOS among this sample to be lower than the general population prevalence of PCOS given the restriction to women of reproductive age and further exclusion of those whose PCOS diagnosis occurred after their index delivery. We would expect any misclassification of our PCOS phenotype to attenuate toward the null for any reported associations in our analysis, suggesting that our findings would be underestimates and not overestimates of the true associations between PCOS and adverse pregnancy outcomes. We were also unable to include data for anyone who had MA Health (Medicaid) during the study period although women both with and without PCOS would have been part of that study population. Given the nature of the linked data in our analysis, people who delivered outside of Massachusetts or who received a PCOS diagnosis outside of Massachusetts may not have been accurately captured in our data. However, we would expect this misclassification to attenuate any reported findings. Our analysis was not able to incorporate information on details related to the PCOS diagnosis, such as phenotype, which has led to heterogeneous findings in previous analyses (Bahri Khomami et al., 2019). Another limitation is that these data come from a single state in the USA and may not reflect conditions found in other states or countries. While we were able to adjust for important confounders such as pre-existing diabetes, hypertension and maternal BMI we do not have information on other important covariates such as gestational weight gain.

In summary, we observed that ∼4% of deliveries in our sample of women with deliveries were to those who had a previous diagnosis of PCOS. While our ability to capture PCOS diagnoses using our linked data source is a considerable strength compared to prior research, this may also be an underestimate of the true disease prevalence, as discussed in detail in the study’s limitations. We observed that women with PCOS were at increased risk of gestational diabetes, hypertensive disorders of pregnancy and cesarean section. Additionally, neonates born to women with a history of PCOS were at increased risk of low birthweight status among full-term deliveries, small for gestational age, preterm birth, prolonged neonatal hospital stay and infectious and respiratory conditions within the first year of life. Prior consensus documents have recognized that women with PCOS may be at increased risk of adverse pregnancy and neonatal outcomes (Fauser et al., 2012; Teede et al., 2018) and the 2018 ‘Recommendations from the international evidence-based guideline for the assessment and management of PCOS’ recommends increased monitoring for women with PCOS during pregnancy given increased risk of adverse offspring outcomes (Teede et al., 2018). Pregnant women should discuss their gynecologic history with their providers and may benefit from additional screening and/or early intervention.

Supplementary Material

deac210_Supplementary_Table_SI
deac210_Supplementary_Table_SII

Acknowledgements

SART wishes to thank all of its members for providing clinical information to the SART CORS database for use by patients and researchers. Without the efforts of our members, this research would not have been possible.

Authors’ roles

L.V.F., S.A.M. and J.E.S. conceived, designed and supervised the study. C.L.-L. and H.J.C. performed and oversaw the statistical analysis. L.V.F., J.E.S., C.L.-L., H.J.C., C.C.C., H.D., D.D., S.H. and S.A.M. drafted and critically reviewed the manuscript and approved the final version.

Funding

This work was supported by the NIH (R01HD067270).

Conflict of interest

S.A.M. receives grant funding from NIH, AbbVie and the Marriot Family Foundation; payment/honoraria from the University of British Columbia, World Endometriosis Research Foundation and Huilun Shanghai; travel support for attending meetings for ESHRE 2019, IASP 2019, National Endometriosis Network UK meeting 2019; SRI 2022, ESHRE 2022; participates on the data safety monitoring board/advisory board for AbbVie, Roche, Frontiers in Reproductive Health; and has a leadership role in the Society for Women’s Health Research, World Endometriosis Research Foundation, World Endometriosis Society, American Society for Reproductive Medicine and ESHRE. The other authors have no conflicts of interest.

Contributor Information

Leslie V Farland, Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA; Department of Obstetrics and Gynecology, College of Medicine-Tucson, University of Arizona, Tucson, AZ, USA.

Judy E Stern, Department of Obstetrics and Gynecology, Dartmouth-Hitchcock, Lebanon, NH, USA.

Chia-Ling Liu, Massachusetts Department of Public Health, Bureau of Family Health and Nutrition, Boston, MA, USA.

Howard J Cabral, Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

Charles C Coddington, III, Department of Obstetrics and Gynecology, Carolinas Medical Center/Atrium Health, Charlotte, NC, USA.

Hafsatou Diop, Massachusetts Department of Public Health, Bureau of Family Health and Nutrition, Boston, MA, USA.

Dmitry Dukhovny, Department of Pediatrics, Oregon Health & Science University, Portland, OR, USA.

Sunah Hwang, Department of Pediatrics, Section of Neonatology, University of Colorado School of Medicine, Aurora, CO, USA.

Stacey A Missmer, Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine Michigan State University, Grand Rapids, MI, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Data Availability

Due to restrictions on release of vital records data by the Massachusetts Department of Public Health we are unable to provide our dataset.

References

  1. Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ.. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity—a systematic review, meta-analysis, and meta-regression. Obes Rev 2019;20:659–674. [DOI] [PubMed] [Google Scholar]
  2. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS.. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673–683. [DOI] [PubMed] [Google Scholar]
  3. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO.. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016;31:2841–2855. [DOI] [PubMed] [Google Scholar]
  4. Correia KF, Dodge LE, Farland LV, Hacker MR, Ginsburg E, Whitcomb BW, Wise LA, Missmer SA.. Confounding and effect measure modification in reproductive medicine research. Hum Reprod 2020;35:1013–1018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Declercq ER, Belanoff C, Diop H, Gopal D, Hornstein MD, Kotelchuck M, Luke B, Stern JE.. Identifying women with indicators of subfertility in a statewide population database: operationalizing the missing link in assisted reproductive technology research. Fertil Steril 2014;101:463–471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Doherty DA, Newnham JP, Bower C, Hart R.. Implications of polycystic ovary syndrome for pregnancy and for the health of offspring. Obstet Gynecol 2015;125:1397–1406. [DOI] [PubMed] [Google Scholar]
  7. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS. et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28–38.e25. [DOI] [PubMed] [Google Scholar]
  8. Foroozanfard F, Asemi Z, Bazarganipour F, Taghavi SA, Allan H, Aramesh S.. Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study. Gynecol Endocrinol 2020;36:61–65. [DOI] [PubMed] [Google Scholar]
  9. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861. [DOI] [PubMed] [Google Scholar]
  10. Gilbert EW, Tay CT, Hiam DS, Teede HJ, Moran LJ.. Comorbidities and complications of polycystic ovary syndrome: an overview of systematic reviews. Clin Endocrinol (Oxf) 2018;89:683–699. [DOI] [PubMed] [Google Scholar]
  11. Hwang SS, Dukhovny D, Gopal D, Cabral H, Missmer S, Diop H, Declercq E, Stern JE.. Health of infants after ART-treated, subfertile, and fertile deliveries. Pediatrics 2018;142:e20174069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kjerulff LE, Sanchez-Ramos L, Duffy D.. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 2011;204:558.e1–6. [DOI] [PubMed] [Google Scholar]
  13. Koster MP, de Wilde MA, Veltman-Verhulst SM, Houben ML, Nikkels PG, van Rijn BB, Fauser BC.. Placental characteristics in women with polycystic ovary syndrome. Hum Reprod 2015;30:2829–2837. [DOI] [PubMed] [Google Scholar]
  14. Kotelchuck M, Hoang L, Stern JE, Diop H, Belanoff C, Declercq E.. The MOSART database: linking the SART CORS clinical database to the population-based Massachusetts PELL reproductive public health data system. Matern Child Health J 2014;18:2167–2178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565–4592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mills G, Badeghiesh A, Suarthana E, Baghlaf H, Dahan MH.. Associations between polycystic ovary syndrome and adverse obstetric and neonatal outcomes: a population study of 9.1 million births. Hum Reprod 2020a;35:1914–1921. [DOI] [PubMed] [Google Scholar]
  17. Mills G, Badeghiesh A, Suarthana E, Baghlaf H, Dahan MH.. Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. Hum Reprod 2020b;35:1666–1674. [DOI] [PubMed] [Google Scholar]
  18. Naver KV, Grinsted J, Larsen SO, Hedley PL, Jørgensen FS, Christiansen M, Nilas L.. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. BJOG 2014;121:575–581. [DOI] [PubMed] [Google Scholar]
  19. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW.. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003;3:6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Palomba S, de Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM.. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update 2015;21:575–592. [DOI] [PubMed] [Google Scholar]
  21. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY.. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013;11:56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sha T, Wang X, Cheng W, Yan Y.. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reprod Biomed Online 2019;39:281–293. [DOI] [PubMed] [Google Scholar]
  23. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ.. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013;28:777–784. [DOI] [PubMed] [Google Scholar]
  24. Stern JE, Liu C-L, Cui X, Gopal D, Cabral HJ, Coddington CC, Missmer SA, Hwang SS, Farland LV, Dukhovny D. et al. Optimizing the control group for evaluating ART outcomes: can outpatient claims data yield a better control group? J Assist Reprod Genet 2021a;38:1089–1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stern JE, Liu C-L, Hwang SS, Dukhovny D, Farland LV, Diop H, Coddington CC, Cabral H.. Influence of placental abnormalities and pregnancy-induced hypertension in prematurity associated with various assisted reproductive technology techniques. JCM 2021b;10:1681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018;110:364–379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Valgeirsdottir H, Sundström Poromaa I, Kunovac Kallak T, Vanky E, Akhter T, Roos N, Stephansson O, Wikström AK.. Polycystic ovary syndrome and extremely preterm birth: a nationwide register-based study. PLoS One 2021;16:e0246743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yu H-F, Chen H-S, Rao D-P, Gong J.. Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e4863. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

deac210_Supplementary_Table_SI
deac210_Supplementary_Table_SII

Data Availability Statement

Due to restrictions on release of vital records data by the Massachusetts Department of Public Health we are unable to provide our dataset.


Articles from Human Reproduction (Oxford, England) are provided here courtesy of Oxford University Press

RESOURCES